文献速递生殖医学

个体化与标准FSH剂量在开始IVF/ICSI女性中的随机对照试验:第一部分:预测低反应者

Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
PubMed 文献 · Hum Reprod · 2017-01-01

这项开放标签多中心随机对照试验纳入511例预测卵巢低反应(AFC<11)的IVF/ICSI女性,比较增加FSH剂量与标准150 IU/day对累积活产率的影响。增加剂量组累积活产率为42.4%(106/250),标准剂量组为44.8%(117/261),两组无显著差异(RR 0.95,95%CI 0.78-1.15,P=0.58),且增加剂量策略费用更高,作者推荐此类女性使用标准剂量150 IU/day。

要点

  • 预测低反应(AFC<11)女性中,增加FSH剂量未提高累积活产率。
  • 增加剂量组累积活产率42.4% vs 标准剂量组44.8%(RR 0.95,95%CI 0.78-1.15)。
  • 作者推荐此类女性使用标准剂量150 IU/day。

核心结论

  • 在预测卵巢低反应(AFC<11)的IVF/ICSI女性中,增加FSH剂量(225/450 IU/day)与标准剂量(150 IU/day)相比未改善累积活产率,且费用更高。
  • 作者推荐此类女性使用标准剂量150 IU/day。

研究设计与样本

  • 开放标签多中心随机对照试验,2011年5月至2014年5月纳入AFC<11的女性,荷兰试验注册号NTR2657。
  • AFC≤7者随机接受FSH 450 IU/day或150 IU/day;AFC 8-10者随机接受225 IU或150 IU/day。
  • 共随机511例,AFC≤7者234例,AFC 8-10者277例;主要结局为随机化后18个月内获得持续妊娠并活产。
  • 样本量计算需300例以检测累积活产率从25%升至40%(双侧α=0.05,把握度80%)。
  • 从意向性治疗角度评估效果与成本效果。

主要发现

  • 增加剂量组累积活产率为42.4%(106/250),标准剂量组为44.8%(117/261),RR 0.95(95%CI 0.78-1.15),P=0.58。
  • 增加剂量策略费用更高,每名女性Δ费用为€1099(95%CI 562-1591),标准FSH剂量在经济分析中为优势策略。

关键数值与推荐

  • 预测低反应定义为AFC<11;AFC≤7随机接受450 IU/day或150 IU/day,AFC 8-10随机接受225 IU或150 IU/day。
  • 标准组允许后续周期根据预设标准调整剂量。
  • 作者推荐对预测低反应(AFC<11)的IVF/ICSI女性使用标准剂量150 IU/day。

临床怎么用

  • 作者推荐对预测低反应(AFC<11)的IVF/ICSI女性使用标准剂量150 IU/day。

局限性

  • 尽管有培训计划,AFC可能存在观察者间变异。
  • 开放研究允许周期间小幅剂量调整,150 IU组可能的选择性取消周期可能影响累积结果。
  • 但首周期活产率方向一致,作者认为开放设计不太可能掩盖个体化策略的潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does an increased FSH dose result in higher cumulative live birth rates in women with a predicted poor ovarian response, apparent from a low antral follicle count (AFC), scheduled for IVF or ICSI? SUMMARY ANSWER: In women with a predicted poor ovarian response (AFC < 11) undergoing IVF/ICSI, an increased FSH dose (225/450 IU/day) does not improve cumulative live birth rates as compared to a standard dose (150 IU/day). WHAT IS KNOWN ALREADY: In women scheduled for IVF/ICSI, an ovarian reserve test (ORT) can predict ovarian response to stimulation. The FSH starting dose is often adjusted based on the ORT from the belief that it will improve live birth rates. However, the existing RCTs on this topic, most of which show no benefit, are underpowered. STUDY DESIGN, SIZE, DURATION: Between May 2011 and May 2014, we performed an open-label multicentre RCT in women with an AFC < 11 (Dutch Trial Register NTR2657). The primary outcome was ongoing pregnancy achieved within 18 months after randomization and resulting in a live birth. We needed 300 women to assess whether an increased dose strategy would increase the cumulative live birth rate from 25 to 40% (two-sided alpha-error 0.05, power 80%). PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with an AFC ≤ 7 were randomized to an FSH dose of 450 IU/day or 150 IU/day, and women with an AFC 8-10 were randomized to 225 IU or 150 IU/day. In the standard group, dose adjustment was allowed in subsequent cycles based on pre-specified criteria. Both effectiveness and cost-effectiveness of the strategies were evaluated from an intention-to-treat perspective. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 511 women were randomized, 234 with an AFC ≤ 7 and 277 with an AFC 8-10. The cumulative live birth rate for increased versus standard dosing was 42.4% (106/250) versus 44.8% (117/261), respectively [relative risk (RR): 0.95 (95%CI, 0.78-1.15), P = 0.58]. As an increased dose strategy was more expensive [delta costs/woman: €1099 (95%CI, 562-1591)], standard FSH dosing was the dominant strategy in our economic analysis. LIMITATIONS, REASONS FOR CAUTION: Despite our training programme, the AFC might have suffered from inter-observer variation. As this open study permitted small dose adjustments between cycles, potential selective cancelling of cycles in women treated with 150 IU could have influenced the cumulative results. However, since first cycle live birth rates point in the same direction we consider it unlikely that the open design masked a potential benefit for the individualized strategy. WIDER IMPLICATIONS OF THE FINDINGS: Since an increased dose in women scheduled for IVF/ICSI with a predicted poor response (AFC < 11) does not improve live birth rates and is more expensive, we recommend using a standard dose of 150 IU/day in these women. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by The Netherlands Organisation for Health Research and Development (ZonMW number 171102020). T.C.T., H.L.T. and S.C.O. received an unrestricted personal grant from Merck BV. H.R.V. receives monetary compensation as a member on an external advisory board for Ferring pharmaceutical BV. B.W.J.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for OvsEva, Merck and Guerbet. F.J.M.B. receives monetary compensation as a member of the external advisory board for Ferring pharmaceutics BV (the Netherlands) and Merck Serono (the Netherlands) for consultancy work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development (Switzerland) and for a research cooperation with Ansh Labs (USA). All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: Registered at the ICMJE-recognized Dutch Trial Registry (www.trialregister.nl). Registration number NTR2657. TRIAL REGISTRATION DATE: 20 December 2010. DATE OF FIRST PATIENT’S ENROLMENT: 12 May 2011.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Tilborg TC, Torrance HL, Oudshoorn SC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder. Hum Reprod. 2017. PMID: 29121326. doi:10.1093/humrep/dex318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。